JSON
Eriksson O, Långström B, Antoni G
Nucl. Med. Biol. 92 (-) 65-71 [2021-01-00; online 2020-04-27]
The understanding of metabolic disease and diabetes on a molecular level has increased significantly due to the recent advances in molecular biology and biotechnology. However, in vitro studies and animal models do not always translate to the human disease, perhaps illustrated by the failure of many drug candidates in the clinical phase. Non-invasive biomedical imaging techniques such as Positron Emission Tomography (PET) offer tools for direct visualization and quantification of molecular processes in humans. Developments in this area potentially enable longitudinal in vivo studies of receptors and processes involved in diabetes guiding drug development and diagnosis in the near future. This mini-review focuses on describing the overall perspective of how PET can be used to increase our understanding and improve treatment of diabetes. The methodological aspects and future developments and challenges are highlighted.
PubMed 32387114
DOI 10.1016/j.nucmedbio.2020.04.004
Crossref 10.1016/j.nucmedbio.2020.04.004
pii: S0969-8051(20)30016-0